Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/9628
Title: Response to parenteral iron therapy distinguish unexplained refractory iron deficiency anemia from iron-refractory iron deficiency anemia
Authors: Akın, Mehmet
Sarbay, Hakan
Güler, Selin
Balcı, Yasemin Işık
Polat, Aziz
Keywords: Anemia
IDA
IRIDA
Refractory
ferritin
hemoglobin
iron saccharate
biological marker
iron
adolescent
Article
child
clinical article
drug effect
drug response
female
ferritin blood level
hemoglobin blood level
human
iron deficiency anemia
iron therapy
male
mean corpuscular hemoglobin
mean corpuscular volume
priority journal
treatment duration
unexplained refractory iron deficiency anemia
Anemia, Iron-Deficiency
blood
differential diagnosis
parenteral nutrition
preschool child
treatment outcome
Adolescent
Biomarkers
Child
Child, Preschool
Diagnosis, Differential
Erythrocyte Indices
Female
Humans
Iron
Male
Parenteral Nutrition
Treatment Outcome
Publisher: Blackwell Publishing Ltd
Abstract: Introduction: We evaluated that response to parenteral iron therapy could be helpful in distinguishing the types of iron deficiency anemia. Patients and Methods: This study analyzed responses to IV iron sucrose therapy of 15 children with unexplained refractory iron deficiency anemia (URIDA). We compared the results at diagnosis, 6 weeks and 6 months after the therapy. Results were compared with responses of 11 patients' results with iron-refractory iron deficiency anemia (IRIDA) from our previous study. Result: Six weeks after the start of treatment, ferritin, MCV, MCH and Hb values were in normal range in 10 patients. The increase in Hb, MCH, MCV, and ferritin values ranged 2.6-3.5 g/dL, 1.7-4.2 pg, 2-9 fL, and 13-25 ng/mL, respectively. In five patients, Hb, MCH, and MCV mean (range) values [11.2 g/dL (11-12.2), 24.5 pg (24-25.6), and 67 fL (65-70)] were nearly normal but ferritin mean (range) values [9.8 ng/mL (8-11)] were below normal. Six weeks after the start of treatment, Hb, MCH, MCV and ferritin values of patients with IRIDA were increased. The increase in Hb, MCH, MCV, and ferritin values ranged 0.8-2.7 g/dL, 1.7-4.2 pg, 2-9 fL, and 13-25 ng/mL, respectively. IRIDA is only partially responsive to parenteral iron supplementation. In conclusion, this study demonstrated that the response to intravenous iron therapy for the URIDA cases improved blood parameters more effectively than hereditary IRIDA. Response to parenteral iron therapy would be helpful to distinguish unexplained refractory IDA from hereditary IRIDA for clinicians who do not have access to hepcidin or TMPRS6 mutation analysis. © 2016 John Wiley & Sons Ltd.
URI: https://hdl.handle.net/11499/9628
https://doi.org/10.1111/ijlh.12462
ISSN: 1751-5521
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

6
checked on Dec 14, 2024

WEB OF SCIENCETM
Citations

4
checked on Dec 19, 2024

Page view(s)

50
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.